F. Buontempo, E. Orsini, M. Ruzzene, J.A. McCubrey, F. Chiarini, A. Cappellini, A. Lonetti, C. Evangelisti, C. Evangelisti, J.T. Barata, A.M. Martelli., Therapeutic targeting of CK2 in acute and chronic leukemias., «LEUKEMIA», 2018, 32, pp. 1 - 10 [Scientific article]Open Access
C. Evangelisti, F. Chiarini, J.A. McCubrey, A.M. Martelli., Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update., «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2018, 19, Article number: 1878 , pp. 1 - 24 [Scientific article]Open Access
Ultimo, S.; Simioni, C.; Martelli, A.M.; Zauli, G.; Evangelisti, C.; Celeghini, C.; Mccubrey, J.A.; Capitani, S.; Neri, L.M. ., PI3K isoforms inhibition associated with anti BCR-ABL1 drugs shows in vitro increased anti-leukemic activity in B-pre acute lymphoblastic leukemia., «ONCOTARGET», 2017, 8, pp. 23213 - 23227 [Scientific article]
Chiarini, F; Lonetti, A; Evangelisti, C; Buontempo, F; Orsini, E; Evangelisti, C; Cappellini, A; Neri, LM; McCubrey, Ja; Martelli, AM., Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting., «BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH», 2016, 1863, pp. 449 - 463 [Scientific article]
Lonetti, A.; Cappellini, A.; Bertaina, A.; Locatelli, F.; Pession, A.; Buontempo, F.; Evangelisti, C.; Evangelisti, C.; Orsini, E.; Zambonin, L.; Neri, L.M.; Martelli, A.M.; Chiarini, F., Improving nelarabine efficacy in T-cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway., «JOURNAL OF HEMATOLOGY & ONCOLOGY», 2016, 9, Article number: 114 , pp. 1 - 16 [Scientific article]Open Access
Evangelisti C.; Cenni V.; Lattanzi G., Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders, «BRITISH JOURNAL OF CLINICAL PHARMACOLOGY», 2016, 82, pp. 1229 - 1244 [Scientific article]
Buontempo, F; Orsini, E; Lonetti, A; Cappellini, A; Chiarini, F; Evangelisti, C; Evangelisti, C; Melchionda, F; Pession, A; Bertaina, A; Locatelli, F; Bertacchini, J; Neri, Lm; Mccubrey, Ja; Martelli, Am., Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the pro-apoptotic NF-κB., «ONCOTARGET», 2016, 7, pp. 1323 - 1340 [Scientific article]Open Access
Evangelisti, C.; Martelli, A.M., The PI3K/Akt/mTOR Pathway, in: Encyclopedia of Cell Biology, Waltham (MA), Academic Press, 2016, pp. 128 - 135 [Chapter or essay]
Evangelisti, C.; Evangelisti, C.; Buontempo, F.; Lonetti, A.; Orsini, E.; Chiarini, F.; Barata, J.T.; Pyne, S.; Pyne, N.J.; Martelli, A.M. ., Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies., «LEUKEMIA», 2016, 30, pp. 2142 - 2151 [Scientific article]
Cecilia Evangelisti; Camilla Evangelisti; Francesca Chiarini; Annalisa Lonetti; Francesca Buontempo; Luca Maria Neri; James A. McCubrey; Alberto Maria Martelli., Autophagy in acute leukemias: a double-edged sword with important therapeutic implications., «BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH», 2015, 1853, pp. 14 - 26 [Scientific article]
F. Chiarini; C. Evangelisti; J. A. McCubrey; A.M. Martelli., Current treatment strategies for inhibiting mTOR in cancer, «TRENDS IN PHARMACOLOGICAL SCIENCES», 2015, 36, pp. 124 - 135 [Scientific article]
Evangelisti, C.; Bernasconi, P.; Cavalcante, P.; Cappelletti, C.; D’Apice, M.R.; Sbraccia, P.; Novelli, G.; Prencipe, S.; Lemma, S.; Baldini, N.; Avnet, S.; Squarzoni, S.; Martelli, A.M.; Lattanzi, G. ., Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins., «ONCOTARGET», 2015, 6, pp. 7424 - 7437 [Scientific article]
Annalisa Lonetti, Alessandra Cappellini, Antonino Maria Spartà, Francesca Chiarini, Francesca Buontempo, Camilla Evangelisti, Cecilia Evangelisti, Ester Orsini, James A. McCubrey, Alberto Maria Martelli, PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors., «ONCOTARGET», 2015, 6, pp. 10399 - 10414 [Scientific article]Open Access
Buontempo F; Orsini E; Cappellini A; Lonetti A; Evangelisti C;
Chiarini F; Spartà AM; Bressanin D; Evangelisti C; Martelli AM, A COMBINATION OF BORTEZOMIB WITH CX-4945, A CASEIN KINASE 2 (CK2)
INHIBITOR, HAS SYNERGISTIC CYTOTOXIC EFFECTS IN ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) CELL LINES, in: Haematologica, «HAEMATOLOGICA», 2014, pp. 82 - 82 (atti di: XIII Congresso della Società italiana di Ematologia Sperimentale, Rimini, 15-17 October 2014) [Poster]
C. Evangelisti; C. Evangelisti; G. Teti; F. Chiarini; M. Falconi; F. Melchionda; A. Pession; A. Bertaina; F. Locatelli; J.A. McCubrey; D. J. Beak; R. Bittman; S. Pyne; N.J. Pyne; A.M. Martelli., Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics., «ONCOTARGET», 2014, 5, pp. 7886 - 7901 [Scientific article]
